The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved event-free survival in resectable gastric and gastroesophageal junction cancers.
AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for the treatment of adults with resectable non-small cell lung cancer.
The FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients with unresectable or metastatic esophageal squamous cell carcinoma whose ...
Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer treatment—SkinJect, a novel microneedle patch designed to eradicate cancerous cells ...
The early findings from the SERENA-6 trial indicate that oral SERD camizestrant provides a “highly statistically significant and clinically meaningful” improvement in progression-free survival for ...
KEYTRUDA (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives FDA priority review based on KEYNOTE-689 results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback